| Objective To investigate the changing trend of serum uric acid levels and its correlation with serum calcium in postmenopausal osteoporotic patients treated with teriparatide, so as to provide assistance for optimizing the safety management of teriparatide therapy. Methods A retrospective analysis was performed on 127 patients treated with teriparatide, including the levels of serum uric acid, serum calcium, parathyroid hormone, procollagen type Ⅰ N-terminal propeptide (PINP) and creatinine at baseline, 2, 4, and 6 months after treatment. Generalized Estimating Equations (GEE) were used to analyze the changing trends of the indicators and the correlation between serum uric acid and serum calcium (adjusted for time, age, and BMI). Results Serum uric acid showed an increasing trend. Based on the GEE model, the marginal mean values were significantly higher than the baseline (with anincrease of 53.19 μmol/L at 2 months, 62.21 μmol/L at 4 months, and 88.70μmol/L at 6 months, all adjusted P<0.001). Additionally, the level at 6 months was higher than that at 2 months (increased by 35.50μmol/L, adjusted P=0.034). The marginal mean of serum calcium increased by 0.11 mmol/L (adjusted P<0.001). PINP continued to rise andparathyroid hormone decreased (both P<0.001). There was no change in creatinine (P=0.092). Serum uric acid was positively correlated with serum calcium level (β=0.405, P<0.001). For each 1 mmol/L increase in serum calcium, the geometric mean of serum uric acid increased by 50.0% [Exp(β)=1.50, 95%CI:1.307～1.719]. Conclusion After treatment with teriparatide in postmenopausal osteoporotic patients, serum uric acid shows a gradually increasing trend and is positively correlated with the increase in serum calcium (β=0.405). During teriparatide treatment, attention should not only be paid to changes in serum calcium but also to regular monitoring of serum uric acid. |